ALK-001 for Stargardt Disease (TEASE Trial)

"Despite there being no evidence of ALK-001's efficacy, the drug has been assigned a safety score of 2 owing to existing clinical data."

"ALK-001 is typically used to address vitamin d deficiencies, but it may also be prescribed for diseases related to vitamin A deficiency and nutritional supplementation."

"This trial necessitates 140 properly qualified candidates, who can be sourced from multiple locations including the University of California Los Angeles - Jules Stein Eye Institute in LA and Columbia University Medical Center - Harkness Eye Institute located in NYC."

"This research project is being conducted at 4 different medical sites, which include Los Angeles, New york and Gainesville. For the convenience of those interested in enrolling, it's crucial to select a clinic close by thus reducing travel time."

"Alkeus Pharmaceuticals, Inc. first began researching ALK-001 in 2015 and conducted a clinical trial with 140 participants that year; it was subsequently granted Phase 2 drug approval. Currently, 8 distinct studies on ALK-001 are ongoing across 10 cities spread over two countries."

"As of now, 8 clinical trials for ALK-001 are active with 2 being in Phase 3. Primarily based in Somerville, MA, 13 different sites across the country have studies involving this drug."

"This research initiative seeks participants aged 8 and above, but below the age of 70."

"Individuals with stargardt disease who are between 8 and 70 years old have the opportunity to apply for this trial. A total of 140 applicants will be accepted."

"Affirmative, clinicaltrials.gov attests that this medical trial is recruiting volunteers for participation. Initially posted on August 1st 2015 and most recently updated on February 15th 2022, the experiment intends to enlist 140 individuals from 4 separate sites."